RA Medical Systems Inc (NYSE:RMED) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $10.33 for the company and are predicting that the company will post ($0.68) EPS for the current quarter, according to Zacks. Zacks has also assigned RA Medical Systems an industry rank of 80 out of 256 based on the ratings given to related companies.

RMED has been the topic of a number of research reports. Piper Jaffray Companies cut shares of RA Medical Systems from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $9.00 to $1.50 in a research note on Tuesday. Zacks Investment Research raised shares of RA Medical Systems from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. Cantor Fitzgerald cut shares of RA Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $10.00 to $2.00 in a research note on Tuesday. Finally, Maxim Group decreased their price target on shares of RA Medical Systems to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th.

Shares of RA Medical Systems stock traded down $1.61 during trading hours on Tuesday, hitting $1.21. The company had a trading volume of 897,085 shares, compared to its average volume of 79,056. The company’s 50-day moving average price is $3.08. RA Medical Systems has a twelve month low of $1.09 and a twelve month high of $22.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 11.45 and a current ratio of 11.89. The firm has a market cap of $35.26 million and a P/E ratio of -0.36.

RA Medical Systems (NYSE:RMED) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.78). The business had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.22 million. Equities research analysts expect that RA Medical Systems will post -3.69 earnings per share for the current fiscal year.

In related news, insider Jeffrey J. Kraws sold 18,021 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $3.08, for a total value of $55,504.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dean Irwin sold 11,800 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $3.27, for a total transaction of $38,586.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,841 shares of company stock worth $176,959. Insiders own 25.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. purchased a new stake in shares of RA Medical Systems during the second quarter valued at approximately $45,000. Weil Company Inc. acquired a new position in RA Medical Systems in the second quarter worth $63,000. BlackRock Inc. acquired a new position in RA Medical Systems in the fourth quarter worth $98,000. Dowling & Yahnke LLC acquired a new position in RA Medical Systems in the second quarter worth $110,000. Finally, Meitav Dash Investments Ltd. boosted its holdings in RA Medical Systems by 18.8% in the first quarter. Meitav Dash Investments Ltd. now owns 118,260 shares of the company’s stock worth $415,000 after purchasing an additional 18,741 shares during the period. Hedge funds and other institutional investors own 20.13% of the company’s stock.

About RA Medical Systems

Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.

See Also: What is Liquidity?

Get a free copy of the Zacks research report on RA Medical Systems (RMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.